513 related articles for article (PubMed ID: 15546192)
1. Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure.
Safavy A; Georg GI; Vander Velde D; Raisch KP; Safavy K; Carpenter M; Wang W; Bonner JA; Khazaeli MB; Buchsbaum DJ
Bioconjug Chem; 2004; 15(6):1264-74. PubMed ID: 15546192
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.
Safavy A; Bonner JA; Waksal HW; Buchsbaum DJ; Gillespie GY; Khazaeli MB; Arani R; Chen DT; Carpenter M; Raisch KP
Bioconjug Chem; 2003; 14(2):302-10. PubMed ID: 12643740
[TBL] [Abstract][Full Text] [Related]
3. Thermosensitive poly(organophosphazene)-paclitaxel conjugate gels for antitumor applications.
Chun C; Lee SM; Kim SY; Yang HK; Song SC
Biomaterials; 2009 Apr; 30(12):2349-60. PubMed ID: 19178941
[TBL] [Abstract][Full Text] [Related]
4. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
Bradley MO; Webb NL; Anthony FH; Devanesan P; Witman PA; Hemamalini S; Chander MC; Baker SD; He L; Horwitz SB; Swindell CS
Clin Cancer Res; 2001 Oct; 7(10):3229-38. PubMed ID: 11595719
[TBL] [Abstract][Full Text] [Related]
5. Contribution of linker stability to the activities of anticancer immunoconjugates.
Alley SC; Benjamin DR; Jeffrey SC; Okeley NM; Meyer DL; Sanderson RJ; Senter PD
Bioconjug Chem; 2008 Mar; 19(3):759-65. PubMed ID: 18314937
[TBL] [Abstract][Full Text] [Related]
6. Novel acid labile COL1 trityl-linked difluoronucleoside immunoconjugates: synthesis, characterization, and biological activity.
Patel VF; Hardin JN; Mastro JM; Law KL; Zimmermann JL; Ehlhardt WJ; Woodland JM; Starling JJ
Bioconjug Chem; 1996; 7(4):497-510. PubMed ID: 8853464
[TBL] [Abstract][Full Text] [Related]
7. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.
Foulon CF; Reist CJ; Bigner DD; Zalutsky MR
Cancer Res; 2000 Aug; 60(16):4453-60. PubMed ID: 10969792
[TBL] [Abstract][Full Text] [Related]
8. Conditionally cleavable radioimmunoconjugates: a novel approach for the release of radioisotopes from radioimmunoconjugates.
Beeson C; Butrynski JE; Hart MJ; Nourigat C; Matthews DC; Press OW; Senter PD; Bernstein ID
Bioconjug Chem; 2003; 14(5):927-33. PubMed ID: 13129395
[TBL] [Abstract][Full Text] [Related]
9. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance.
Hamann PR; Hinman LM; Beyer CF; Greenberger LM; Lin C; Lindh D; Menendez AT; Wallace R; Durr FE; Upeslacis J
Bioconjug Chem; 2005; 16(2):346-53. PubMed ID: 15769088
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer.
Almqvist Y; Steffen AC; Tolmachev V; Divgi CR; Sundin A
Nucl Med Biol; 2006 Nov; 33(8):991-8. PubMed ID: 17127172
[TBL] [Abstract][Full Text] [Related]
11. Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting.
van Schaijk FG; Broekema M; Oosterwijk E; van Eerd JE; McBride BJ; Goldenberg DM; Corstens FH; Boerman OC
J Nucl Med; 2005 Jun; 46(6):1016-22. PubMed ID: 15937314
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel.
Zhang C; Qu G; Sun Y; Wu X; Yao Z; Guo Q; Ding Q; Yuan S; Shen Z; Ping Q; Zhou H
Biomaterials; 2008 Mar; 29(9):1233-41. PubMed ID: 18093646
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice.
Schluep T; Cheng J; Khin KT; Davis ME
Cancer Chemother Pharmacol; 2006 May; 57(5):654-62. PubMed ID: 16133526
[TBL] [Abstract][Full Text] [Related]
14. Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity.
Guillemard V; Saragovi HU
Cancer Res; 2001 Jan; 61(2):694-9. PubMed ID: 11212270
[TBL] [Abstract][Full Text] [Related]
15. Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia.
Hauck ML; Zalutsky MR
Int J Hyperthermia; 2005 Feb; 21(1):1-11. PubMed ID: 15764347
[TBL] [Abstract][Full Text] [Related]
16. Hydrotropic oligomer-conjugated glycol chitosan as a carrier of paclitaxel: synthesis, characterization, and in vivo biodistribution.
Saravanakumar G; Min KH; Min DS; Kim AY; Lee CM; Cho YW; Lee SC; Kim K; Jeong SY; Park K; Park JH; Kwon IC
J Control Release; 2009 Dec; 140(3):210-7. PubMed ID: 19560497
[TBL] [Abstract][Full Text] [Related]
17. Antibody-indocyanin conjugates for immunophotodetection of human squamous cell carcinoma in nude mice.
Folli S; Westermann P; Braichotte D; Pèlegrin A; Wagnières G; van den Bergh H; Mach JP
Cancer Res; 1994 May; 54(10):2643-9. PubMed ID: 8168092
[TBL] [Abstract][Full Text] [Related]
18. Site-specifically radioiodinated antibody for targeting tumors.
Rea DW; Ultee ME; Belinka BA; Coughlin DJ; Alvarez VL
Cancer Res; 1990 Feb; 50(3 Suppl):857s-861s. PubMed ID: 2297734
[TBL] [Abstract][Full Text] [Related]
19. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
[TBL] [Abstract][Full Text] [Related]
20. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
van Schaijk FG; Oosterwijk E; Molkenboer-Kuenen JD; Soede AC; McBride BJ; Goldenberg DM; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2005 Mar; 46(3):495-501. PubMed ID: 15750164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]